HUTCHMED CHINA-ADR (HCM) Stock Price, Quote, News and Overview
NASDAQ:HCM - Nasdaq - US44842L1035 - ADR - Currency: USD
HCM Quote, Performance and Key Statistics
NASDAQ:HCM (2/21/2025, 8:25:13 PM)
16.11
+0.78 (+5.09%)
The current stock price of HCM is 16.11 USD. In the past month the price increased by 18.46%. In the past year, price increased by 2.48%.
HCM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About HCM
Company Profile
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,970 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Company Info
HUTCHMED CHINA-ADR
48th Floor, Cheung Kong Center, 2 Queen's Road Central
Hong Kong HK
CEO: Christian Hogg
Employees: 1970
Company Website: https://www.hutch-med.com/
Investor Relations: https://www.hutch-med.com/shareholder-information/
Phone: 85221281188
HUTCHMED CHINA-ADR / HCM FAQ
What is the stock price of HUTCHMED CHINA-ADR today?
The current stock price of HCM is 16.11 USD. The price increased by 5.09% in the last trading session.
What is the ticker symbol for HUTCHMED CHINA-ADR stock?
The exchange symbol of HUTCHMED CHINA-ADR is HCM and it is listed on the Nasdaq exchange.
On which exchange is HCM stock listed?
HCM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HUTCHMED CHINA-ADR stock?
25 analysts have analysed HCM and the average price target is 16.26 USD. This implies a price increase of 0.91% is expected in the next year compared to the current price of 16.11. Check the HUTCHMED CHINA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HUTCHMED CHINA-ADR worth?
HUTCHMED CHINA-ADR (HCM) has a market capitalization of 2.75B USD. This makes HCM a Mid Cap stock.
How many employees does HUTCHMED CHINA-ADR have?
HUTCHMED CHINA-ADR (HCM) currently has 1970 employees.
What are the support and resistance levels for HUTCHMED CHINA-ADR (HCM) stock?
HUTCHMED CHINA-ADR (HCM) has a support level at 14 and a resistance level at 16.12. Check the full technical report for a detailed analysis of HCM support and resistance levels.
Is HUTCHMED CHINA-ADR (HCM) expected to grow?
The Revenue of HUTCHMED CHINA-ADR (HCM) is expected to decline by -16.15% in the next year. Check the estimates tab for more information on the HCM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HUTCHMED CHINA-ADR (HCM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HCM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HCM, evaluating the profitability, health, valuation and growth aspects
- HUTCHMED CHINA-ADR (HCM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HUTCHMED CHINA-ADR (HCM) Sales and EPS estimates to see what analysts future expectations are.
- HUTCHMED CHINA-ADR (HCM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HUTCHMED CHINA-ADR (HCM) Insider and Institutional Ownership to learn about the owners and their transactions.
- HUTCHMED CHINA-ADR (HCM) Stock Chart to make your own analysis
- HUTCHMED CHINA-ADR (HCM) Latest news and press-releases to stay up to date.
Does HUTCHMED CHINA-ADR (HCM) stock pay dividends?
HCM does not pay a dividend.
When does HUTCHMED CHINA-ADR (HCM) report earnings?
HUTCHMED CHINA-ADR (HCM) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of HUTCHMED CHINA-ADR (HCM)?
HUTCHMED CHINA-ADR (HCM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the Short Interest ratio of HUTCHMED CHINA-ADR (HCM) stock?
The outstanding short interest for HUTCHMED CHINA-ADR (HCM) is 0.42% of its float. Check the ownership tab for more information on the HCM short interest.
HCM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HCM. When comparing the yearly performance of all stocks, HCM is a bad performer in the overall market: 65.73% of all stocks are doing better.
HCM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HCM. While HCM seems to be doing ok healthwise, there are quite some concerns on its profitability.
HCM Financial Highlights
Over the last trailing twelve months HCM reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -25.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.33% | ||
| ROE | -5.67% | ||
| Debt/Equity | 0.11 |
HCM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to HCM. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of -312.35% and a revenue growth -16.15% for HCM